Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment

PRINCETON, N.J.--(BUSINESS WIRE) August 1, 2017 -- Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of adult and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news